Zenbexus introduces a next-generation cereblon-based protein degrader into an established three-drug treatment strategy for relapsed multiple myeloma.
Key Takeaways
- The FDA granted accelerated approval to Zenbexus (iberdomide) as part of a three-drug regimen for previously treated multiple myeloma.
- The new regimen replaces bortezomib in an established Darzalex-based combination with iberdomide, BMS’s next-generation CELMoD protein degrader.
- IberDd achieved an MRD-negative complete response rate of 41% versus 21% with the comparator DVd regimen, although progression-free survival data are still maturing.
Data Snapshot
| Item | Details |
|---|---|
| Product | Zenbexus |
| Generic name | Iberdomide |
| Developer | Bristol Myers Squibb |
| Drug class | CELMoD |
| Target | Cereblon E3 ubiquitin ligase |
| Approved regimen | Iberdomide + Darzalex + dexamethasone |
| Comparator | Darzalex + bortezomib + dexamethasone |
| Phase 3 trial | EXCALIBER-RRMM |
| MRD-negative CR | 41% vs. 21% |
| Regulatory pathway | FDA accelerated approval |
The key comparison is straightforward: both regimens contain Darzalex and dexamethasone, but the investigational arm replaces bortezomib with iberdomide.
What Happened
The FDA granted accelerated approval to Zenbexus (iberdomide) in combination with subcutaneous daratumumab/hyaluronidase and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. (FDA approval announcement)
In the Phase 3 EXCALIBER-RRMM trial, the new IberDd regimen—iberdomide, Darzalex and dexamethasone—was compared with DVd, an established regimen combining Darzalex, bortezomib and dexamethasone. The MRD-negative complete response rate was 41% with IberDd versus 21% with DVd in the primary efficacy population. (Reuters report)
Why It Matters
Iberdomide is the first approved member of the CELMoD (cereblon E3 ligase modulator) class. Rather than directly blocking a conventional cancer target, CELMoDs bind cereblon and redirect the cell’s protein-degradation machinery toward proteins such as Ikaros and Aiolos, promoting myeloma-cell killing while also stimulating immune activity. (BMS’s overview of the CELMoD program)
The trial design also makes the result easier to interpret. Darzalex and dexamethasone were retained in both arms, meaning much of the differentiation came from replacing the proteasome inhibitor bortezomib with iberdomide. In that context, the higher MRD-negative complete response rate provides an early signal that the CELMoD approach may deepen treatment responses beyond the established DVd regimen.
For BMS, Zenbexus is also part of a broader targeted protein degradation strategy. The company is developing another CELMoD, mezigdomide, whose FDA application is already under review for relapsed or refractory multiple myeloma. (BMS’s mezigdomide update)
However, accelerated approval means the clinical story remains incomplete. EXCALIBER-RRMM is continuing to evaluate progression-free survival, and confirmation of durable clinical benefit will be critical to validating whether deeper MRD responses translate into longer disease control.
BP View
Zenbexus is interesting because it does not simply add another drug to an already crowded multiple myeloma market. It replaces one component of an established three-drug regimen with a next-generation protein degrader and produced a substantially deeper response by the MRD endpoint.
For patients with relapsed multiple myeloma, another effective treatment option is welcome, particularly as resistance to existing therapies accumulates over successive lines of treatment.
At the same time, the 41% MRD-negative complete response rate also highlights how much unmet need remains. Nearly six in ten patients did not reach this deep level of response, reminding us that even a meaningful improvement over existing therapy does not eliminate the challenge of treatment resistance and persistent disease. Closing that remaining gap will continue to be an important challenge in multiple myeloma treatment.
For BMS, the approval provides the first regulatory validation of its CELMoD strategy and extends the company’s long-standing experience with cereblon-directed therapies into a more potent generation of targeted protein degraders.
The remaining question is the most important one: will the improvement in MRD-negative complete responses ultimately translate into longer progression-free survival and meaningful clinical benefit for patients?

Related Post
For another recent look at Bristol Myers Squibb’s strategic position, read our previous analysis of investor resistance to a reported $400 billion AstraZeneca–BMS megadeal.
About BP
Biopharma Perspective (BP) explains global biopharma news through strategic, clinical and market perspectives.


Leave a Reply